GIM
ALNY icon

Generali Investments Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Generali Investments Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Sell
946
-281
-23% -$84.8K 0.06% 137
2026
Q1 		$406K Buy
1,227
+262
+27% +$89.2K 0.09% 116
2025
Q4 		$384K Buy
+965
New +$427K 0.08% 114

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Generali Investments Management's ALNY Position: Q2 2026 in Review

Generali Investments Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 23% in Q2 2026, selling an estimated $84.8K and leaving 946 shares worth $285K. The position accounts for 0.06% of the portfolio, ranked #137.

Generali Investments Management first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $406K in Q1 2026. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Generali Investments Management held 946 shares of Alnylam Pharmaceuticals worth $285K as of Q2 2026.
  • Generali Investments Management sold 281 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $84.8K.
  • Alnylam Pharmaceuticals made up 0.06% of Generali Investments Management's portfolio in Q2 2026, its #137 holding.
  • Generali Investments Management first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Generali Investments Management's Alnylam Pharmaceuticals position peaked at $406K in Q1 2026.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Generali Investments Management's 13F filing for Q2 2026, filed 10 Jul 2026.